A new report highlights more than 75 drugs under consideration for Duchenne muscular dystrophy, promising significant progress in patient care. The analysis explores clinical strategies, upcoming therapies, and commercial prospects, signaling a major shift in the DMD landscape.

Eric Olson, Ph.D., of UT Southwestern Medical Center, has been awarded the 2025 Louisa Gross Horwitz Prize for his pioneering research on the genetic control of muscle development and emerging treatments for Duchenne muscular dystrophy. His work paves the way for critical breakthroughs in combating a life-threatening condition affecting both skeletal and cardiac muscle.